ArcticZymes Technologies (AZT) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue ranged from NOK 24.4 million to NOK 26.4 million, down year-over-year but up sequentially, reflecting a broader customer base and improved commercial execution.

• EBITDA for Q4 was NOK 2.7 million, a significant year-over-year improvement, with adjusted EBITDA of NOK 4.1 million after extraordinary items.

• 2024 was a year of transformation, including reorganization, closure of the Oslo site, and a shift to a customer-centric commercial model.

• Two new GMP-compliant SAN products and a new ERP system were launched to support operational efficiency and scalability.

• Leadership and commercial organization were strengthened, positioning for long-term growth and deeper customer partnerships.

Financial highlights

• Q4 sales revenue was NOK 24.4–24.5 million, down from NOK 28.4 million in Q4 2023; full-year sales were NOK 104.4 million, down 12% from 2023.

• EBITDA for Q4 was NOK 2.7 million (up from NOK 1.9 million in Q4 2023); adjusted EBITDA was NOK 4.1 million, excluding ERP project costs.

• Q4 EBITDA margin improved to 20% from -10% in Q3 2024.

• Cash and short-term investments at year-end ranged from NOK 170.9 million to over NOK 240 million; no interest-bearing debt.

• Product gross margins remained above 90% across all products.

Outlook and guidance

• A new GMP-grade nuclease will launch mid-2025, finalizing the regulatory upgrade campaign.

• Focus in 2025 will shift more toward molecular tools and RNA innovation, with continued commercial transformation and customer-centric strategies.

• Strategic CDMO partnership to integrate M-SAN into viral vector manufacturing, anticipated as a long-term revenue driver.

• Return to growth expected in 2025, supported by new products, partnerships, and improved market conditions.